Benefits of SGLT2i for the Treatment of Heart Failure Irrespective of Diabetes Diagnosis: A State-of-the-Art Review.
- Published in:
- Diabetes Therapy, 2022, v. 13, n. 1, p. 19, doi. 10.1007/s13300-022-01278-0
- By:
- Publication type:
- Article
Works matching IS 18696953 AND DT 2022 AND VI 13 AND IP 1
Results: 19
1
2
SGLT2 Inhibitors and the Cardiorenal Continuum: A Paradigm Shift in the Treatment of Patients with T2D.
- Published in:
- Diabetes Therapy, 2022, v. 13, n. 1, p. 1, doi. 10.1007/s13300-022-01281-5
- By:
- Publication type:
- Article
3
Prevention of Cardiorenal Complications with Sodium–Glucose Cotransporter Type 2 Inhibitors: A Narrative Review.
- Published in:
- Diabetes Therapy, 2022, v. 13, n. 1, p. 5, doi. 10.1007/s13300-022-01277-1
- By:
- Publication type:
- Article
4
Review of SGLT2i for the Treatment of Renal Complications: Experience in Patients with and Without T2D.
- Published in:
- Diabetes Therapy, 2022, v. 13, n. 1, p. 35, doi. 10.1007/s13300-022-01276-2
- By:
- Publication type:
- Article
5
Early Worsening of Retinopathy in Type 1 and Type 2 Diabetes After Rapid Improvement in Glycaemic Control: A Systematic Review.
- Published in:
- Diabetes Therapy, 2022, v. 13, n. 1, p. 1, doi. 10.1007/s13300-021-01190-z
- By:
- Publication type:
- Article
6
Higher Rates of Persistence and Adherence in Patients with Type 2 Diabetes Initiating Once-Weekly vs Daily Injectable Glucagon-Like Peptide-1 Receptor Agonists in US Clinical Practice (STAY Study).
- Published in:
- Diabetes Therapy, 2022, v. 13, n. 1, p. 175, doi. 10.1007/s13300-021-01189-6
- By:
- Publication type:
- Article
7
Are There Different Viewpoints About the Management of Type 2 Diabetes Mellitus and Comorbidities? A Multidisciplinary Spanish Qualitative Research.
- Published in:
- Diabetes Therapy, 2022, v. 13, n. 1, p. 189, doi. 10.1007/s13300-021-01188-7
- By:
- Publication type:
- Article
8
A Response to the Letter to the Editor Regarding "Nationwide Prevalence of Diabetes and Prediabetes and Associated Risk Factors Among Iranian Adults: Analysis of Data from PERSIAN Cohort Study" to the end of Study.
- Published in:
- Diabetes Therapy, 2022, v. 13, n. 1, p. 221, doi. 10.1007/s13300-021-01187-8
- By:
- Publication type:
- Article
9
Letter to the Editor Regarding "Nationwide Prevalence of Diabetes and Prediabetes and Associated Risk Factors Among Iranian Adults: Analysis of Data from PERSIAN Cohort Study".
- Published in:
- Diabetes Therapy, 2022, v. 13, n. 1, p. 217, doi. 10.1007/s13300-021-01186-9
- By:
- Publication type:
- Article
10
Comparing Real-World Effectiveness of Dulaglutide and Insulin as the First Injectable for Patients with Type 2 Diabetes: An Australian Single-Site Retrospective Chart Review.
- Published in:
- Diabetes Therapy, 2022, v. 13, n. 1, p. 131, doi. 10.1007/s13300-021-01184-x
- By:
- Publication type:
- Article
11
Prognostic Value of Stress Hyperglycemia in Patients Admitted to Medical/Geriatric Departments for Acute Medical Illness.
- Published in:
- Diabetes Therapy, 2022, v. 13, n. 1, p. 145, doi. 10.1007/s13300-021-01183-y
- By:
- Publication type:
- Article
12
Efficacy of Dulaglutide in Chinese Patients with Type 2 Diabetes and Different Glycemic Patterns: a Post-hoc Analysis of the Phase 3 AWARD-CHN2 Trial.
- Published in:
- Diabetes Therapy, 2022, v. 13, n. 1, p. 161, doi. 10.1007/s13300-021-01182-z
- By:
- Publication type:
- Article
13
Insulin Pump Treatment in Adults with Type 1 Diabetes in the Capital Region of Denmark: Design and Cohort Characteristics of the Steno Tech Survey.
- Published in:
- Diabetes Therapy, 2022, v. 13, n. 1, p. 113, doi. 10.1007/s13300-021-01181-0
- By:
- Publication type:
- Article
14
Concomitant iGlarLixi and Sodium-Glucose Co-transporter-2 Inhibitor Therapy in Adults with Type 2 Diabetes: LixiLan-G Trial and Real-World Evidence Results.
- Published in:
- Diabetes Therapy, 2022, v. 13, n. 1, p. 205, doi. 10.1007/s13300-021-01180-1
- By:
- Publication type:
- Article
15
Does Gender Influence the Effectiveness and Safety of Insulin Glargine 300 U/ml in Patients with Uncontrolled Type 2 Diabetes? Results from the REALI European Pooled Analysis.
- Published in:
- Diabetes Therapy, 2022, v. 13, n. 1, p. 57, doi. 10.1007/s13300-021-01179-8
- By:
- Publication type:
- Article
16
Patient Preferences for Pharmacological Diabetes Treatment Among People with Diabetes in Spain: A Discrete Choice Experiment.
- Published in:
- Diabetes Therapy, 2022, v. 13, n. 1, p. 75, doi. 10.1007/s13300-021-01178-9
- By:
- Publication type:
- Article
17
Improved Glycemic Control Observed in Children with Type 1 Diabetes Following the Introduction of Smart Insulin Pens: A Real-World Study.
- Published in:
- Diabetes Therapy, 2022, v. 13, n. 1, p. 43, doi. 10.1007/s13300-021-01177-w
- By:
- Publication type:
- Article
18
Gut Microbiome Activity Contributes to Prediction of Individual Variation in Glycemic Response in Adults.
- Published in:
- Diabetes Therapy, 2022, v. 13, n. 1, p. 89, doi. 10.1007/s13300-021-01174-z
- By:
- Publication type:
- Article
19
Healthcare Costs and Resource Utilization Associated with the Use of Empagliflozin Versus Other Antihyperglycemic Agents Among Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease: A Real-World Retrospective Cohort Analysis.
- Published in:
- Diabetes Therapy, 2022, v. 13, n. 1, p. 25, doi. 10.1007/s13300-021-01173-0
- By:
- Publication type:
- Article